122.620 s

-2.380 (-1.90%)
Range 122.410 - 124.960   (2.08%)
Open 124.810
Previous Close 125.000
Bid Price 78.630
Bid Volume 8
Ask Price 78.820
Ask Volume 8
Volume 4,939,345
Value -
Remark s
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events

About Gilead Sciences

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

There are 11 followers

Pen
Followers
3
I'm just going to share my INV thoughts and reading notes here
Followers
47
Followers
1
Followers
0
Followers
0
Followers
0
FOUNDER, SGSTOCKSINVESTING.COM
Followers
774
Followers
0
Followers
0
Followers
2
Followers
65